Fluorination Of 3-(3-(Piperidin-1-Yl)Propyl)Indoles And 3-(3-(Piperazin-1-Yl)Propyl)Indoles Gives Selective Human 5-Ht1d Receptor Ligands With Improved Pharmacokinetic Profiles

Monique B. van Niel,Ian Collins,Margaret S. Beer,Howard B. Broughton, Susan K. F. Cheng, Simon C. Goodacre,Anne Heald, Karen L. Locker,Angus M. MacLeod, Denise Morrison, Christopher R. Moyes, Desmond O'Connor, Andrew Pike,Michael Rowley,Michael G. N. Russell, Balbinder Sohal,Josephine A. Stanton,Steven Thomas, Hugh Verrier,Alan P. Watt,José L. Castro

Cheminform(1999)

引用 151|浏览5
暂无评分
摘要
It has previously been reported that a 3-(3-(piperazin-1-yl)propyl)indole series of 5-HT1D receptor ligands have pharmacokinetic advantages over the-corresponding 3-(3-(piperidin-1-yl)propyl)indole series and that the reduced pK(a) of the piperazines compared to the piperidines may be one possible explanation for these differences. To investigate this proposal we have developed versatile synthetic strategies for the incorporation of fluorine into these ligands, producing novel series of 4-fluoropiperidines, 3-fluoro-4-aminopiperidines, and both piperazine and piperidine derivatives with one or two fluorines in the propyl linker. Ligands were identified which maintained high affinity and selectivity for the 5-HT1D receptor and showed agonist efficacy in vitro. The incorporation of fluorine was found to significantly reduce the pK(a) of the compounds, and this reduction of basicity was shown to have a dramatic, beneficial influence on oral absorption, although the effect on oral bioavailability could not always be accurately predicted.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要